Cronos Price To Sales Ratio Over Time

CRON Stock  CAD 2.79  0.08  2.95%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cronos Performance and Cronos Correlation.
  
As of the 23rd of December 2024, Price To Sales Ratio is likely to drop to 8.66.
Please note, there is a significant difference between Cronos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cronos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cronos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Price To Sales Ratio Analysis

Compare Cronos Group and related stocks such as Aurora Cannabis, Canopy Growth Corp, and OrganiGram Holdings Price To Sales Ratio Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
ACB7.8 K4264264264264263347733.32355.84847.726816.49821.30321.02620.97
WEED15815815815853815831872884617.85727.44047.12972.72782.5672538
OGI0.98070.98070.98070.98070.98070.98070.98070.98070.98070.98070.98070.98070.98071.59983.0085

Cronos Group and related stocks such as Aurora Cannabis, Canopy Growth Corp, and OrganiGram Holdings Price To Sales Ratio description

Price to Sales Ratio is figured by comparing Cronos Group stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cronos sales, a figure that is much harder to manipulate than other Cronos Group multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

My Equities

My Current Equities and Potential Positions

Cronos Group
CRON
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Business Address111 Peter Street,
ExchangeToronto Exchange
CAD 2.79
When determining whether Cronos Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cronos' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cronos Group Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cronos Group Stock:
Check out Cronos Performance and Cronos Correlation.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Cronos technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Cronos technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Cronos trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...